Related Experiment Video
Updated: Jan 9, 2026

Testing the Role of Multicopy Plasmids in the Evolution of Antibiotic Resistance
Published on: May 2, 2018
Antibiotic-Adjuvants Abolish Resistance Conferred by the Staphylococcus aureus Erythromycin Resistance
Taylor S Barber1, John N Alumasa1
1Department of Chemistry and Biochemistry, Miami University, Oxford, Ohio 45056, United States.
Abstract:
Enzyme-mediated resistance is among the main strategies that bacteria use to evade antibiotic action. S-Adenosylmethionine-dependent erythromycin resistance methyltransferases catalyze the methylation of 23S rRNA in bacteria, causing resistance to macrolides, lincosamides, and streptogramin type-B antibiotics. Given the diversity and number of identified variants of these enzymes, it is vital to devise ways of inhibiting their activity to rescue affected antibiotics. Here, we use computer-aided solvent mapping and virtual screening techniques to identify inhibitors of Erms displaying promising adjuvant properties. We further demonstrate that an E. coli model expressing a recombinant S. aureus ErmC (SaErmC) variant causes substantial resistance to representative macrolide and lincosamide antibiotics. Assessment of test compounds using this resistance model revealed candidates that displayed promising adjuvant activity when combined with erythromycin or clindamycin. Antibiotic combinations with a principal candidate oxadiazole, JNAL-016, completely blocked SaErmC-mediated resistance against erythromycin, resulting in an antibiotic-sensitive phenotype in broth microdilution screening assays. This compound also suppressed ErmC activity, allowing erythromycin to regain its bactericidal properties when assessed in actively growing cultures using time-kill assays. JNAL-016 displayed a noncompetitive mode of inhibition against SaErmC activity in vitro and bound the purified enzyme with high affinity (Kd = 1.8 ± 0.7 μM) based on microscale thermophoresis data. Competition experiments suggested that JNAL-016 competes with SAM for its binding pocket on the enzyme, and this compound exhibited no toxicity against human embryonic kidney cells. These findings establish a practical strategy for targeting Erm-mediated resistance, which could lead to a viable adjuvant-based therapy against bacterial pathogens that weaponize variants of this class of methyltransferases.
More Related Videos
10:41The Logic, Experimental Steps, and Potential of Heterologous Natural Product Biosynthesis Featuring the Complex Antibiotic Erythromycin A Produced Through E. coli
Published on: January 13, 2013
10:49Antibiotic Dereplication Using the Antibiotic Resistance Platform
Published on: October 17, 2019
Related Concept Videos
Development of Antibiotic Resistance
Antibiotic Selection
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Gene Regulation in Microbial Communities: Quorum Sensing
Mismatch Repair